Alzheimer’s disease is a growing global concern. As populations age, more people are being affected by this condition, which slowly takes away memory and thinking ability. It is the most common cause of dementia, and currently, there is no cure.
Scientists have been trying for many years to find treatments that can stop or slow the disease. Recently, attention has turned to an unexpected group of medicines. These are GLP-1 receptor agonists, which are mainly used to treat type 2 diabetes and help with weight loss.
A new review study from Anglia Ruskin University, published in Molecular and Cellular Neuroscience, examined whether these drugs could also help with Alzheimer’s disease. The researchers looked at 30 earlier studies involving four drugs: liraglutide, semaglutide, exenatide, and dulaglutide.
To understand the importance of this research, it helps to know how Alzheimer’s disease affects the brain. Two main problems are involved.
First, a protein called amyloid-beta builds up and forms plaques outside brain cells. Second, another protein called tau becomes abnormal and forms tangles inside brain cells. Together, these changes disrupt communication between cells and lead to cell death.
The review found that many studies showed these drugs could reduce both amyloid-beta and tau. More than three-quarters of the studies reported a reduction in at least one of these harmful proteins. This suggests that GLP-1 drugs may help address the root causes of Alzheimer’s disease, not just the symptoms.
Liraglutide showed the most consistent results, reducing both types of harmful proteins in many studies. Semaglutide and dulaglutide also showed encouraging effects, although there were fewer studies. Exenatide produced mixed results, with some studies showing benefits and others not.
While these findings are encouraging, most of the evidence comes from laboratory and animal studies. Human research is still in its early stages. In one human trial, liraglutide was given for six months. It did not improve memory or reduce protein buildup, but it did help maintain brain energy use.
Another study tested exenatide over a longer period. It did not show clear changes in the main disease markers in brain fluid, but it did reduce amyloid-beta in certain small particles. These particles may reflect early disease changes, so this result may still be meaningful.
Researchers believe these drugs may help the brain in several ways. They may reduce inflammation, improve how brain cells handle energy, and influence how harmful proteins are formed. These effects could protect the brain before serious damage occurs.
When analyzing the findings, it becomes clear that the drugs may not reverse Alzheimer’s disease once it is advanced. Instead, they may be more useful in the early stages or even before symptoms appear. This shifts the focus from treatment to prevention.
However, there are still important limitations. The number of human studies is small, and results are not yet strong enough to confirm real benefits for patients. Larger clinical trials are needed to test whether these drugs can slow memory loss or delay the onset of the disease.
Despite these challenges, the research is important. It suggests that existing drugs could be repurposed to fight a completely different disease. This could speed up the development of new treatments, since these drugs are already approved for other uses.
In conclusion, this study offers a hopeful direction for Alzheimer’s research. While more work is needed, GLP-1 drugs may one day become part of strategies to prevent or slow this devastating condition.
If you care about brain health, please read studies about inflammation that may actually slow down cognitive decline in older people, and low vitamin D may speed up cognitive decline.
For more health information, please see recent studies about common exercises that could protect against cognitive decline, and results showing that this MIND diet may protect your cognitive function, prevent dementia.
Source: Anglia Ruskin University.
